董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James S. Shannon | 男 | Director | 69 | 26.77万美元 | 未持股 | 2017-03-16 |
| Ronald Consiglio | 男 | Director | 81 | 25.45万美元 | 未持股 | 2017-03-16 |
| Michael Friedman | 男 | Director | 81 | 23.14万美元 | 未持股 | 2017-03-16 |
| Kent Kresa | 男 | Chairman of the Board of Directors | 87 | 27.72万美元 | 未持股 | 2017-03-16 |
| David H. MacCallum | 男 | Director | 87 | 23.19万美元 | 未持股 | 2017-03-16 |
| Matthew J. Pfeffer | 男 | Chief Executive Officer, Chief Financial Officer and Director | 59 | 122.10万美元 | 未持股 | 2017-03-16 |
| Henry L. Nordhoff | 男 | Director | 83 | 23.19万美元 | 未持股 | 2017-03-16 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Raymond W. Urbanski | 男 | Corporate Vice President, Chief Medical Officer | 57 | 未披露 | 未持股 | 2017-03-16 |
| Joseph Kocinsky | 男 | Corporate Vice President, Chief Technology Officer | 53 | 86.44万美元 | 未持股 | 2017-03-16 |
| Michael E. Castagna | 男 | Corporate Vice President, Chief Commercial Officer | 40 | 未披露 | 未持股 | 2017-03-16 |
| Rosabel R. Alinaya | 女 | Senior Vice President, Principal Accounting Officer | 56 | 未披露 | 未持股 | 2017-03-16 |
| Matthew J. Pfeffer | 男 | Chief Executive Officer, Chief Financial Officer and Director | 59 | 122.10万美元 | 未持股 | 2017-03-16 |
| David B. Thomson | 男 | Corporate Vice President, General Counsel and Secretary | 50 | 112.29万美元 | 未持股 | 2017-03-16 |
| Stuart A. Tross | 男 | Corporate Vice President, Chief People Officer | 50 | 未披露 | 未持股 | 2017-03-16 |
董事简历
中英对照 | 中文 | 英文- James S. Shannon
-
James S. Shannon，英国磁共振胰胆管造影专业医学博士，从2010年2月以来是我们董事会的成员。从2009年1月至2011年4月，James S. Shannon担任生物制药公司Cerimon Pharmaceuticals的总裁和首席执行官；从2008年10月到2011年8月，他在该公司担任董事。从1994年12月到2008年9月，Shannon博士曾在保健产品公司Novartis AG担任各种行政职务，其中从2005年11月到2008年9月担任其全球医药发展部主管。他是生物制药公司MannKind Corporatio（从2011年2月起2）、Crucell（从2010年6月到2011年2月）、Biotie Therapies（从2010年4月起）和其它几个私有公司的董事会成员。James S. Shannon拥有贝尔法斯特女王大学授予医学学士学位、生物化学硕士学位、 外科医学学士学位、产科学学士学位及医学博士学位，并且是英国皇家医师学院（Royal College of Physicians （UK））的成员。
James S. Shannon rejoined our board in May 2015 after previously serving as a director from February 2010 until April 2012. From May 2012 until his retirement in April 2015 Dr. Shannon was the Chief Medical Officer of GlaxoSmithKline. He formerly held the position of Global Head of Pharma Development at Novartis AG, based in Basel, Switzerland from 2005 until 2008. After joining Sandoz in 1994 as Head of Drug Regulatory Affairs, Dr. Shannon led of the Integration Office for R&D overseeing the creation of the Novartis R&D groups from those of Ciba-Geigy Ltd and Sandoz. Following the merger he was appointed Head of the Cardiovascular Strategic Team and subsequently became Global Head of Project Management before being appointed Global Head of Clinical Development and Medical Affairs in 1999 a position that he held until 2005 when he was appointed to Head Pharma Development. Between 2008 and joining GSK, Dr. Shannon served on the boards of a number of companies, including Biotie, Circassia, Crucell, Endocyte and MannKind. He also sat on the board of Cerimon Pharmaceuticals where he held the position of interim Chief Executive Officer and President from January 2009 until April 2010. He first entered the pharmaceutical industry in 1987 joining Sterling Winthrop Inc., working initially in Europe and subsequently in the USA, where he held positions of increasing responsibility in the management of research and development ultimately serving as Senior Vice-President, Clinical Development. Dr. Shannon is trained in Medicine and Cardiology. He received his undergraduate and postgraduate degrees at Queen's University of Belfast and is a Member of the Royal College of Physicians UK. - James S. Shannon，英国磁共振胰胆管造影专业医学博士，从2010年2月以来是我们董事会的成员。从2009年1月至2011年4月，James S. Shannon担任生物制药公司Cerimon Pharmaceuticals的总裁和首席执行官；从2008年10月到2011年8月，他在该公司担任董事。从1994年12月到2008年9月，Shannon博士曾在保健产品公司Novartis AG担任各种行政职务，其中从2005年11月到2008年9月担任其全球医药发展部主管。他是生物制药公司MannKind Corporatio（从2011年2月起2）、Crucell（从2010年6月到2011年2月）、Biotie Therapies（从2010年4月起）和其它几个私有公司的董事会成员。James S. Shannon拥有贝尔法斯特女王大学授予医学学士学位、生物化学硕士学位、 外科医学学士学位、产科学学士学位及医学博士学位，并且是英国皇家医师学院（Royal College of Physicians （UK））的成员。
- James S. Shannon rejoined our board in May 2015 after previously serving as a director from February 2010 until April 2012. From May 2012 until his retirement in April 2015 Dr. Shannon was the Chief Medical Officer of GlaxoSmithKline. He formerly held the position of Global Head of Pharma Development at Novartis AG, based in Basel, Switzerland from 2005 until 2008. After joining Sandoz in 1994 as Head of Drug Regulatory Affairs, Dr. Shannon led of the Integration Office for R&D overseeing the creation of the Novartis R&D groups from those of Ciba-Geigy Ltd and Sandoz. Following the merger he was appointed Head of the Cardiovascular Strategic Team and subsequently became Global Head of Project Management before being appointed Global Head of Clinical Development and Medical Affairs in 1999 a position that he held until 2005 when he was appointed to Head Pharma Development. Between 2008 and joining GSK, Dr. Shannon served on the boards of a number of companies, including Biotie, Circassia, Crucell, Endocyte and MannKind. He also sat on the board of Cerimon Pharmaceuticals where he held the position of interim Chief Executive Officer and President from January 2009 until April 2010. He first entered the pharmaceutical industry in 1987 joining Sterling Winthrop Inc., working initially in Europe and subsequently in the USA, where he held positions of increasing responsibility in the management of research and development ultimately serving as Senior Vice-President, Clinical Development. Dr. Shannon is trained in Medicine and Cardiology. He received his undergraduate and postgraduate degrees at Queen's University of Belfast and is a Member of the Royal College of Physicians UK.
- Ronald Consiglio
-
Ronald Consiglio，2003年10月，他成为我们的董事。1999年开始他是协同公司（Synergy Trading 证券交易合伙公司）的董事总经理。1999年到2001年，他是优势交易公司（Trading Edge, Inc. 一个国家的自动债券交易公司）的执行副总裁和首席财务官。1993年1月到1998年，他是洛杉矶的抵押贷款投资信托（Mortgage Investment Trust 公开交易的房地产投资信托）的首席执行官。他先前的经验包括Cantor Fitzgerald & Co.公司的高级副总裁和首席财务官和董事会成员。他目前是都市西部基金（Metropolitan West Funds）董事会一员。他是注册会计师，持有美国加利福尼亚州立大学（California State University ）会计学士学位。
Ronald Consiglio has been one of our directors since October 2003. Since 1999 Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001 Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor's degree in accounting from California State University at Northridge. - Ronald Consiglio，2003年10月，他成为我们的董事。1999年开始他是协同公司（Synergy Trading 证券交易合伙公司）的董事总经理。1999年到2001年，他是优势交易公司（Trading Edge, Inc. 一个国家的自动债券交易公司）的执行副总裁和首席财务官。1993年1月到1998年，他是洛杉矶的抵押贷款投资信托（Mortgage Investment Trust 公开交易的房地产投资信托）的首席执行官。他先前的经验包括Cantor Fitzgerald & Co.公司的高级副总裁和首席财务官和董事会成员。他目前是都市西部基金（Metropolitan West Funds）董事会一员。他是注册会计师，持有美国加利福尼亚州立大学（California State University ）会计学士学位。
- Ronald Consiglio has been one of our directors since October 2003. Since 1999 Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001 Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor's degree in accounting from California State University at Northridge.
- Michael Friedman
-
Michael Friedman，2003年12月开始就是董事。2003年就是希望城国家医学中心（the City of Hope National Medical Center）的首席执行官和总裁。2001年9月到2003年4月，他是法玛西亚公司（Pharmacia Corporation）研究和发展部，医疗和公共政策部的高级副总裁。1999年7月到2001年9月，他是赛尔公司（Searle 孟山都公司Monsanto Company的子公司）的高级副总裁。1995年到1999年6月，他是食品和药物管理局（Food and Drug Administration）营运部的副税务长。1997年到1998年，他是代理专员和副专员。他获得路易斯安那新奥尔良的杜兰大学（Tulane University）的文学学士学位，是优等生。他获得来自德克萨斯大学（the University of Texas）西南医学院的医学博士学位。
Michael Friedman, M.D. has served as one of the company's directors since February 2011 and a member of the Nominating Committee since April 2011. Dr. Friedman is the emeritus Chief Executive Officer of City of Hope, a leading cancer research, treatment and education institution, as well as Director of the organization’s Comprehensive Cancer Center and holder of the Irell & Manella Cancer Center Director’s Distinguished Chair. Before leading City of Hope, Dr. Friedman was Senior Vice President of Research and Development, Medical and Public Policy for Pharmacia Corporation and Chief Medical Officer for biomedical preparedness at PhRMA. Additionally, Dr. Friedman has served as Deputy Commissioner for the U.S. Food and Drug Administration FDA, later serving as Acting Commissioner, and as Associate Director of the National Cancer Institute, National Institutes of Health. Since 2004 Dr. Friedman has served on the Independent Citizens’ Oversight Committee which governs the California Institute for Regenerative Medicine and oversees the implementation of California’s stem cell research effort. Dr. Friedman is a member of the Board of Directors of MannKind Corporation, Smith & Nephew plc. and Intuitive Surgical, Inc. He also serves on the Board of Trustees for Tulane University. - Michael Friedman，2003年12月开始就是董事。2003年就是希望城国家医学中心（the City of Hope National Medical Center）的首席执行官和总裁。2001年9月到2003年4月，他是法玛西亚公司（Pharmacia Corporation）研究和发展部，医疗和公共政策部的高级副总裁。1999年7月到2001年9月，他是赛尔公司（Searle 孟山都公司Monsanto Company的子公司）的高级副总裁。1995年到1999年6月，他是食品和药物管理局（Food and Drug Administration）营运部的副税务长。1997年到1998年，他是代理专员和副专员。他获得路易斯安那新奥尔良的杜兰大学（Tulane University）的文学学士学位，是优等生。他获得来自德克萨斯大学（the University of Texas）西南医学院的医学博士学位。
- Michael Friedman, M.D. has served as one of the company's directors since February 2011 and a member of the Nominating Committee since April 2011. Dr. Friedman is the emeritus Chief Executive Officer of City of Hope, a leading cancer research, treatment and education institution, as well as Director of the organization’s Comprehensive Cancer Center and holder of the Irell & Manella Cancer Center Director’s Distinguished Chair. Before leading City of Hope, Dr. Friedman was Senior Vice President of Research and Development, Medical and Public Policy for Pharmacia Corporation and Chief Medical Officer for biomedical preparedness at PhRMA. Additionally, Dr. Friedman has served as Deputy Commissioner for the U.S. Food and Drug Administration FDA, later serving as Acting Commissioner, and as Associate Director of the National Cancer Institute, National Institutes of Health. Since 2004 Dr. Friedman has served on the Independent Citizens’ Oversight Committee which governs the California Institute for Regenerative Medicine and oversees the implementation of California’s stem cell research effort. Dr. Friedman is a member of the Board of Directors of MannKind Corporation, Smith & Nephew plc. and Intuitive Surgical, Inc. He also serves on the Board of Trustees for Tulane University.
- Kent Kresa
-
Kent Kresa，自2004六月起一直担任本公司董事。从1990九月起，他担任国防公司Northrop Grumman Corporation的荣誉主席，直到2003十月，此后他担任该公司董事长。从1990一月到2003三月，他担任首席执行官；从1987到2001九月，他担任总裁。他现任加州理工学院的理事会主席，并从1994起成为该学院理事会成员。他担任着 Fluor Corporation，一些非营利组织和大学的董事。他也是西方信托公司的咨询委员会成员。他毕业于麻省理工学院，于1959年获得学士学位，1961获得硕士学位，1966成为航空学和航天学工程师。
Kent Kresa has been a member of Board of Directors since June 2004 and has served as Chairman of the Board since February 2016. From November 2011 until his appointment as Chairman, Mr. Kresa served on Board of Directors as lead independent director. Mr. Kresa is Chairman Emeritus of Northrop Grumman Corporation, a defense company and from September 1990 until October 2003 he was also its Chairman. He also served as Chief Executive Officer of Northrop Grumman Corporation from January 1990 until March 2003 and as its President from 1987 until September 2001. From 2003 to August 2010 Mr. Kresa served as a director of General Motors Company or its predecessor. From December 2005 to April 2010 Mr. Kresa served as a director of Avery Dennison Corporation. Mr. Kresa has been a member of the Caltech Board of Trustees since 1994. Mr. Kresa has served on the board of Fluor Corporation since 2003 and he also serves on the boards of several non-profit organizations and universities. As a graduate of Massachusetts Institute of Technology, he received a B.S. in 1959 an M.S. in 1961 and an E.A.A. in 1966 all in aeronautics and astronautics. - Kent Kresa，自2004六月起一直担任本公司董事。从1990九月起，他担任国防公司Northrop Grumman Corporation的荣誉主席，直到2003十月，此后他担任该公司董事长。从1990一月到2003三月，他担任首席执行官；从1987到2001九月，他担任总裁。他现任加州理工学院的理事会主席，并从1994起成为该学院理事会成员。他担任着 Fluor Corporation，一些非营利组织和大学的董事。他也是西方信托公司的咨询委员会成员。他毕业于麻省理工学院，于1959年获得学士学位，1961获得硕士学位，1966成为航空学和航天学工程师。
- Kent Kresa has been a member of Board of Directors since June 2004 and has served as Chairman of the Board since February 2016. From November 2011 until his appointment as Chairman, Mr. Kresa served on Board of Directors as lead independent director. Mr. Kresa is Chairman Emeritus of Northrop Grumman Corporation, a defense company and from September 1990 until October 2003 he was also its Chairman. He also served as Chief Executive Officer of Northrop Grumman Corporation from January 1990 until March 2003 and as its President from 1987 until September 2001. From 2003 to August 2010 Mr. Kresa served as a director of General Motors Company or its predecessor. From December 2005 to April 2010 Mr. Kresa served as a director of Avery Dennison Corporation. Mr. Kresa has been a member of the Caltech Board of Trustees since 1994. Mr. Kresa has served on the board of Fluor Corporation since 2003 and he also serves on the boards of several non-profit organizations and universities. As a graduate of Massachusetts Institute of Technology, he received a B.S. in 1959 an M.S. in 1961 and an E.A.A. in 1966 all in aeronautics and astronautics.
- David H. MacCallum
-
David H. MacCallum，2004年6月开始就是董事。2002年开始他是外群岛资本公司（Outer Islands Capital 专注于卫生保健投资的对冲基金）的任事股东。1999年6月到2001年11月，他是所罗门美邦（Salomon Smith Barney 金融机构花旗银行Citigroup 的一部分）卫生保健投资银行的全球负责人。在加入所罗门美邦（Salomon Smith Barney）前，1998年4他到1999年6月，他是ING Barings Furman Selz 公司（投资银行公司和ING集团的子公司）的健康保健集团的执行副总裁和领导。ING集团是荷兰一家金融机构。在这之前，1994年5月到1998年4月，他组建了瑞银证券（UBS Securities 投资银行公司）的生命科学集团，在那儿他是生命科学部的董事总经理和全球领导人。在加入瑞银证券（UBS Securities ）前，他建立了汉博奎斯特公司（Hambrecht & Quist 投资银行公司）的健康保健部。在那儿他担任了健康保健部的领导，和银行投资部的联席领导。2005年到2010年10月，他是Zymogenetics公司的董事。2002年到2008年，他是生命征象公司（Zymogenetics, Inc.）的董事。他从布朗大学（Brown University）获得学士学位。他获得了来自纽约大学（New York University）的工商管理硕士学位。他是特许金融分析师。
David H. MacCallum has been one of our directors since June 2004. Since 2002 Mr. MacCallum has served as the Managing Partner of Outer Islands Capital, a hedge fund specializing in health care investments. From June 1999 until November 2001 he was Global Head of Health Care investment banking for Salomon Smith Barney, part of Citigroup, a financial institution. Prior to joining Salomon Smith Barney, he was Executive Vice President and Head of the Health Care group at ING Barings Furman Selz LLC, an investment banking firm and subsidiary of ING Group, a Dutch financial institution, from April 1998 to June 1999. Prior to that, Mr. MacCallum formed the Life Sciences group at UBS Securities, an investment banking firm, where he was Managing Director and Global Head of Life Sciences from May 1994 to April 1998. Before joining UBS Securities, he built the health care practice at Hambrecht & Quist, an investment banking firm, where he was Head of Health Care and Co-Head of Investment Banking. From 2005 to October 2010 Mr. MacCallum served as a director of Zymogenetics, Inc. From 2002 to 2008 he served as a director of Vital Signs, Inc. Mr. MacCallum received an A.B. degree from Brown University and an M.B.A. degree from New York University. He is a Chartered Financial Analyst. - David H. MacCallum，2004年6月开始就是董事。2002年开始他是外群岛资本公司（Outer Islands Capital 专注于卫生保健投资的对冲基金）的任事股东。1999年6月到2001年11月，他是所罗门美邦（Salomon Smith Barney 金融机构花旗银行Citigroup 的一部分）卫生保健投资银行的全球负责人。在加入所罗门美邦（Salomon Smith Barney）前，1998年4他到1999年6月，他是ING Barings Furman Selz 公司（投资银行公司和ING集团的子公司）的健康保健集团的执行副总裁和领导。ING集团是荷兰一家金融机构。在这之前，1994年5月到1998年4月，他组建了瑞银证券（UBS Securities 投资银行公司）的生命科学集团，在那儿他是生命科学部的董事总经理和全球领导人。在加入瑞银证券（UBS Securities ）前，他建立了汉博奎斯特公司（Hambrecht & Quist 投资银行公司）的健康保健部。在那儿他担任了健康保健部的领导，和银行投资部的联席领导。2005年到2010年10月，他是Zymogenetics公司的董事。2002年到2008年，他是生命征象公司（Zymogenetics, Inc.）的董事。他从布朗大学（Brown University）获得学士学位。他获得了来自纽约大学（New York University）的工商管理硕士学位。他是特许金融分析师。
- David H. MacCallum has been one of our directors since June 2004. Since 2002 Mr. MacCallum has served as the Managing Partner of Outer Islands Capital, a hedge fund specializing in health care investments. From June 1999 until November 2001 he was Global Head of Health Care investment banking for Salomon Smith Barney, part of Citigroup, a financial institution. Prior to joining Salomon Smith Barney, he was Executive Vice President and Head of the Health Care group at ING Barings Furman Selz LLC, an investment banking firm and subsidiary of ING Group, a Dutch financial institution, from April 1998 to June 1999. Prior to that, Mr. MacCallum formed the Life Sciences group at UBS Securities, an investment banking firm, where he was Managing Director and Global Head of Life Sciences from May 1994 to April 1998. Before joining UBS Securities, he built the health care practice at Hambrecht & Quist, an investment banking firm, where he was Head of Health Care and Co-Head of Investment Banking. From 2005 to October 2010 Mr. MacCallum served as a director of Zymogenetics, Inc. From 2002 to 2008 he served as a director of Vital Signs, Inc. Mr. MacCallum received an A.B. degree from Brown University and an M.B.A. degree from New York University. He is a Chartered Financial Analyst.
- Matthew J. Pfeffer
-
Matthew J. Pfeffer，2008年4月开始就是公司的副总裁和首席财务官。2006年3月到2008年4月，他是VaxGen公司的财务和行政管理部的首席财务官和高级副总裁，担任了责任越来越大的财政，税收，财政，人力资源，采购，设施功能职位。在加入公司前，他是细胞软件公司（Cell Genesys）的首席财务官。在他在细胞软件公司（Cell Genesys）的9年工作中，他是财务部主任，在1998年被任命为首席财务官前。在这之前，他在其他公司担任不同的财务管理职位任职，包括公司财务主管，内部审计经理和财务报告经理。他毕业于伯克利加利福尼亚大学（the University of California），是注册会计师。
Matthew J. Pfeffer has served as our Chief Executive Officer and one of our directors since January 2016 and as our Chief Financial Officer since April 2008. Mr. Pfeffer also served as our Corporate Vice President from April 2008 until January 2016. Previously, Mr. Pfeffer served as Chief Financial Officer and Senior Vice President of Finance and Administration of VaxGen, Inc. from March 2006 until April 2008 with responsibility for finance, tax, treasury, human resources, IT, purchasing and facilities functions. Prior to VaxGen, Mr. Pfeffer served as CFO of Cell Genesys, Inc. During his nine year tenure at Cell Genesys, Mr. Pfeffer served as Director of Finance before being named CFO in 1998. Prior to that, Mr. Pfeffer served in a variety of financial management positions at other companies, including roles as Corporate Controller, Manager of Internal Audit and Manager of Financial Reporting. Mr. Pfeffer began his career at Price Waterhouse. Mr. Pfeffer graduated from the University of California, Berkeley and is a Certified Public Accountant. - Matthew J. Pfeffer，2008年4月开始就是公司的副总裁和首席财务官。2006年3月到2008年4月，他是VaxGen公司的财务和行政管理部的首席财务官和高级副总裁，担任了责任越来越大的财政，税收，财政，人力资源，采购，设施功能职位。在加入公司前，他是细胞软件公司（Cell Genesys）的首席财务官。在他在细胞软件公司（Cell Genesys）的9年工作中，他是财务部主任，在1998年被任命为首席财务官前。在这之前，他在其他公司担任不同的财务管理职位任职，包括公司财务主管，内部审计经理和财务报告经理。他毕业于伯克利加利福尼亚大学（the University of California），是注册会计师。
- Matthew J. Pfeffer has served as our Chief Executive Officer and one of our directors since January 2016 and as our Chief Financial Officer since April 2008. Mr. Pfeffer also served as our Corporate Vice President from April 2008 until January 2016. Previously, Mr. Pfeffer served as Chief Financial Officer and Senior Vice President of Finance and Administration of VaxGen, Inc. from March 2006 until April 2008 with responsibility for finance, tax, treasury, human resources, IT, purchasing and facilities functions. Prior to VaxGen, Mr. Pfeffer served as CFO of Cell Genesys, Inc. During his nine year tenure at Cell Genesys, Mr. Pfeffer served as Director of Finance before being named CFO in 1998. Prior to that, Mr. Pfeffer served in a variety of financial management positions at other companies, including roles as Corporate Controller, Manager of Internal Audit and Manager of Financial Reporting. Mr. Pfeffer began his career at Price Waterhouse. Mr. Pfeffer graduated from the University of California, Berkeley and is a Certified Public Accountant.
- Henry L. Nordhoff
-
Henry L. Nordhoff，2013年6月进入董事会。他于2011年底从 Gen-Probe Incorporated（一家临床诊断及血液筛查公司）的董事长职位退休，他自2002年9月起担任其董事长。1994年7月至2009年5月，Nordhoff先生也是Gen-Probe的首席执行官兼总裁。在加入Gen-Probe之前，他是TargeTech, Inc.（一家基因疗法公司，与Immune Response Corporation合并）的总裁兼首席执行官。他早前在Pfizer, Inc.在布鲁塞尔、首尔、东京及纽约担任高管职位。他是MannKind Corporation（一家生物制药公司）的董事，2011年之前也是Gen-Probe的董事。他获得了Johns Hopkins University的国际关系学和政治经济学双学士学位，Columbia University的工商管理硕士学位。
Henry L. Nordhoff has been one of our directors since March 2005. He has served as a director of BioTime, Inc. since June 2013 and as a director of Asterias Biotherapeutics, Inc. since October 2013. Mr. Nordhoff retired as Chairman of the Board of Gen-Probe Incorporated, a clinical diagnostic and blood screening company, at the end of 2011 after serving as its Chairman since September 2002. He also served as Chief Executive Officer and President of Gen-Probe from July 1994 until May 2009. Prior to joining Gen-Probe, he was President and Chief Executive Officer of TargeTech, Inc., a gene therapy company that was merged into Immune Response Corporation. - Henry L. Nordhoff，2013年6月进入董事会。他于2011年底从 Gen-Probe Incorporated（一家临床诊断及血液筛查公司）的董事长职位退休，他自2002年9月起担任其董事长。1994年7月至2009年5月，Nordhoff先生也是Gen-Probe的首席执行官兼总裁。在加入Gen-Probe之前，他是TargeTech, Inc.（一家基因疗法公司，与Immune Response Corporation合并）的总裁兼首席执行官。他早前在Pfizer, Inc.在布鲁塞尔、首尔、东京及纽约担任高管职位。他是MannKind Corporation（一家生物制药公司）的董事，2011年之前也是Gen-Probe的董事。他获得了Johns Hopkins University的国际关系学和政治经济学双学士学位，Columbia University的工商管理硕士学位。
- Henry L. Nordhoff has been one of our directors since March 2005. He has served as a director of BioTime, Inc. since June 2013 and as a director of Asterias Biotherapeutics, Inc. since October 2013. Mr. Nordhoff retired as Chairman of the Board of Gen-Probe Incorporated, a clinical diagnostic and blood screening company, at the end of 2011 after serving as its Chairman since September 2002. He also served as Chief Executive Officer and President of Gen-Probe from July 1994 until May 2009. Prior to joining Gen-Probe, he was President and Chief Executive Officer of TargeTech, Inc., a gene therapy company that was merged into Immune Response Corporation.
高管简历
中英对照 | 中文 | 英文- Raymond W. Urbanski
Raymond W. Urbanski，是医学博士和哲学博士；2015年8月起，担任我们首席医疗官。此前，2012年9月-2014年9月，担任Mylan, Inc.首席医疗官；2011年10月-2012年6月，担任Metabolex, Inc. 首席医疗官。2004年6月-2011年10月，在Pfizer Inc.担任数个职位，最近担任副总裁和成立产品事业部医疗负责人。还曾在Suntory Pharmaceutical, Inc. 担任研发副总裁和首席医疗官；他持有新泽西医学与牙科大学（University of Medicine and Dentistry of New Jersey）的医学博士学位和药理毒理博士学位。他在费城Thomas Jefferson University Hospital完成了他的住院医师和研究员培训。
Raymond W. Urbanski has been our Chief Medical Officer since August 2015. Prior to joining us, he served as Chief Medical Officer at Mylan, Inc. from September 2012 to September 2014 and Chief Medical Officer at Metabolex, Inc. from October 2011 to June 2012. From June 2004 to October 2011 Dr. Urbanski held several positions with Pfizer Inc. most recently as Vice President and Medical Head of the Established Products Business Unit. He also served as Vice President of Research and Development and Chief Medical Officer at Suntory Pharmaceutical, Inc. Dr. Urbanski earned both his M.D. and Ph.D. in pharmacology and toxicology at the University of Medicine and Dentistry of New Jersey. He completed his residency and fellowship training at Thomas Jefferson University Hospital in Philadelphia.- Raymond W. Urbanski，是医学博士和哲学博士；2015年8月起，担任我们首席医疗官。此前，2012年9月-2014年9月，担任Mylan, Inc.首席医疗官；2011年10月-2012年6月，担任Metabolex, Inc. 首席医疗官。2004年6月-2011年10月，在Pfizer Inc.担任数个职位，最近担任副总裁和成立产品事业部医疗负责人。还曾在Suntory Pharmaceutical, Inc. 担任研发副总裁和首席医疗官；他持有新泽西医学与牙科大学（University of Medicine and Dentistry of New Jersey）的医学博士学位和药理毒理博士学位。他在费城Thomas Jefferson University Hospital完成了他的住院医师和研究员培训。
- Raymond W. Urbanski has been our Chief Medical Officer since August 2015. Prior to joining us, he served as Chief Medical Officer at Mylan, Inc. from September 2012 to September 2014 and Chief Medical Officer at Metabolex, Inc. from October 2011 to June 2012. From June 2004 to October 2011 Dr. Urbanski held several positions with Pfizer Inc. most recently as Vice President and Medical Head of the Established Products Business Unit. He also served as Vice President of Research and Development and Chief Medical Officer at Suntory Pharmaceutical, Inc. Dr. Urbanski earned both his M.D. and Ph.D. in pharmacology and toxicology at the University of Medicine and Dentistry of New Jersey. He completed his residency and fellowship training at Thomas Jefferson University Hospital in Philadelphia.
- Joseph Kocinsky
Joseph Kocinsky，2015年10月起，担任我们企业副总裁、技术总监。他有着超过28年的医药行业科技业务和产品开发经验。2003年加入我们前，他在Schering-Plough Corp.担任各种技术和管理重要职位。持有New Jersey Institute of Technology 的化学工程学士学位和生物医学工程硕士学位，以及Seton Hall 大学的工商管理硕士学位。
Joseph Kocinsky has been our Corporate Vice President, Chief Technology Officer since October 2015. Mr. Kocinsky has over 28 years of experience in the pharmaceutical industry in technical operations and product development. Prior to joining us in 2003 he held a variety of technical and management positions with increased responsibility at Schering-Plough Corp. Mr. Kocinsky holds a bachelor’s degree in chemical engineering and a master’s degree in Biomedical Engineering from New Jersey Institute of Technology and a master’s degree in business administration from Seton Hall University.- Joseph Kocinsky，2015年10月起，担任我们企业副总裁、技术总监。他有着超过28年的医药行业科技业务和产品开发经验。2003年加入我们前，他在Schering-Plough Corp.担任各种技术和管理重要职位。持有New Jersey Institute of Technology 的化学工程学士学位和生物医学工程硕士学位，以及Seton Hall 大学的工商管理硕士学位。
- Joseph Kocinsky has been our Corporate Vice President, Chief Technology Officer since October 2015. Mr. Kocinsky has over 28 years of experience in the pharmaceutical industry in technical operations and product development. Prior to joining us in 2003 he held a variety of technical and management positions with increased responsibility at Schering-Plough Corp. Mr. Kocinsky holds a bachelor’s degree in chemical engineering and a master’s degree in Biomedical Engineering from New Jersey Institute of Technology and a master’s degree in business administration from Seton Hall University.
- Michael E. Castagna
Michael E. Castagna，2016年3月以来，他一直是我们的首席商业官。2012年11月至加入MannKind公司，他曾任职Amgen, Inc.，在那里他最初担任全球生命周期管理副总裁，最近担任Amgen公司的副总裁、生物仿制药业务单元的全球商业领导。从2010年到2012年，他担任Bristol-Myers Squibb的免疫学执行主管。任职BMS公司之前，他曾担任Sandoz公司的北美生物制药的副总裁兼主管。他也曾担任EMD Merck Serono、Pharmasset、DuPont Pharmaceuticals的商业领导。他持有University of the Sciences-Philadelphia College of Pharmacy的药学学位、Massachusetts College of Pharmacy & Sciences的药学博士学位，以及宾夕法尼亚大学沃顿商学院（The Wharton School of Business at the University of Pennsylvania）的工商管理硕士学位。
Michael E. Castagna has been our Chief Commercial Officer since March 2016. From November 2012 until he joined MannKind, Dr. Castagna was at Amgen, Inc., where he initially served as Vice President, Global Lifecycle Management and was most recently Vice President, Global Commercial Lead for Amgen’s Biosimilar Business Unit. From 2010 to 2012 he was Executive Director, Immunology, at Bristol-Myers Squibb. Before BMS, Dr. Castagna served as Vice President & Head, Biopharmaceuticals, North America, at Sandoz. He has also held positions with commercial responsibilities at EMD Merck Serono, Pharmasset and DuPont Pharmaceuticals. He received his pharmacy degree from University of the Sciences-Philadelphia College of Pharmacy, a Doctor of Pharmacy from Massachusetts College of Pharmacy & Sciences and an MBA from The Wharton School of Business at the University of Pennsylvania.- Michael E. Castagna，2016年3月以来，他一直是我们的首席商业官。2012年11月至加入MannKind公司，他曾任职Amgen, Inc.，在那里他最初担任全球生命周期管理副总裁，最近担任Amgen公司的副总裁、生物仿制药业务单元的全球商业领导。从2010年到2012年，他担任Bristol-Myers Squibb的免疫学执行主管。任职BMS公司之前，他曾担任Sandoz公司的北美生物制药的副总裁兼主管。他也曾担任EMD Merck Serono、Pharmasset、DuPont Pharmaceuticals的商业领导。他持有University of the Sciences-Philadelphia College of Pharmacy的药学学位、Massachusetts College of Pharmacy & Sciences的药学博士学位，以及宾夕法尼亚大学沃顿商学院（The Wharton School of Business at the University of Pennsylvania）的工商管理硕士学位。
- Michael E. Castagna has been our Chief Commercial Officer since March 2016. From November 2012 until he joined MannKind, Dr. Castagna was at Amgen, Inc., where he initially served as Vice President, Global Lifecycle Management and was most recently Vice President, Global Commercial Lead for Amgen’s Biosimilar Business Unit. From 2010 to 2012 he was Executive Director, Immunology, at Bristol-Myers Squibb. Before BMS, Dr. Castagna served as Vice President & Head, Biopharmaceuticals, North America, at Sandoz. He has also held positions with commercial responsibilities at EMD Merck Serono, Pharmasset and DuPont Pharmaceuticals. He received his pharmacy degree from University of the Sciences-Philadelphia College of Pharmacy, a Doctor of Pharmacy from Massachusetts College of Pharmacy & Sciences and an MBA from The Wharton School of Business at the University of Pennsylvania.
- Rosabel R. Alinaya
RosabelR.Alinaya自2016年1月以来一直担任我们的高级副总裁，首席会计官，负责财务，会计，税务，财务，投资者关系和风险管理。此前，她曾担任我们的财务Vice President（2011年3月以来），此前曾担任我们的公司总会计师（2003年6月以来）。Alinaya女士在德勤会计师事务所（Deloitte&Touche LLP）开始她的职业生涯，毕业于加州州立大学北岭分校（California State University，Northridge），是一名注册会计师。她还是美国注册会计师协会（American Institute of Certified Public Accountants）的成员和加州注册会计师协会（California Society of Certified Public Accountants）的成员。
Rosabel R. Alinaya has been our Senior Vice President, Principal Accounting Officer since January 2016 with responsibility for finance, accounting, tax, treasury, investor relations and risk management. Previously, she was our Vice President, Finance since March 2011 after serving as our Corporate Controller since June 2003. Ms. Alinaya began her career at Deloitte & Touche LLP, graduating from California State University, Northridge and is a Certified Public Accountant. She is also a member of the American Institute of Certified Public Accountants and a member of the California Society of Certified Public Accountants.- RosabelR.Alinaya自2016年1月以来一直担任我们的高级副总裁，首席会计官，负责财务，会计，税务，财务，投资者关系和风险管理。此前，她曾担任我们的财务Vice President（2011年3月以来），此前曾担任我们的公司总会计师（2003年6月以来）。Alinaya女士在德勤会计师事务所（Deloitte&Touche LLP）开始她的职业生涯，毕业于加州州立大学北岭分校（California State University，Northridge），是一名注册会计师。她还是美国注册会计师协会（American Institute of Certified Public Accountants）的成员和加州注册会计师协会（California Society of Certified Public Accountants）的成员。
- Rosabel R. Alinaya has been our Senior Vice President, Principal Accounting Officer since January 2016 with responsibility for finance, accounting, tax, treasury, investor relations and risk management. Previously, she was our Vice President, Finance since March 2011 after serving as our Corporate Controller since June 2003. Ms. Alinaya began her career at Deloitte & Touche LLP, graduating from California State University, Northridge and is a Certified Public Accountant. She is also a member of the American Institute of Certified Public Accountants and a member of the California Society of Certified Public Accountants.
- Matthew J. Pfeffer
Matthew J. Pfeffer，2008年4月开始就是公司的副总裁和首席财务官。2006年3月到2008年4月，他是VaxGen公司的财务和行政管理部的首席财务官和高级副总裁，担任了责任越来越大的财政，税收，财政，人力资源，采购，设施功能职位。在加入公司前，他是细胞软件公司（Cell Genesys）的首席财务官。在他在细胞软件公司（Cell Genesys）的9年工作中，他是财务部主任，在1998年被任命为首席财务官前。在这之前，他在其他公司担任不同的财务管理职位任职，包括公司财务主管，内部审计经理和财务报告经理。他毕业于伯克利加利福尼亚大学（the University of California），是注册会计师。
Matthew J. Pfeffer has served as our Chief Executive Officer and one of our directors since January 2016 and as our Chief Financial Officer since April 2008. Mr. Pfeffer also served as our Corporate Vice President from April 2008 until January 2016. Previously, Mr. Pfeffer served as Chief Financial Officer and Senior Vice President of Finance and Administration of VaxGen, Inc. from March 2006 until April 2008 with responsibility for finance, tax, treasury, human resources, IT, purchasing and facilities functions. Prior to VaxGen, Mr. Pfeffer served as CFO of Cell Genesys, Inc. During his nine year tenure at Cell Genesys, Mr. Pfeffer served as Director of Finance before being named CFO in 1998. Prior to that, Mr. Pfeffer served in a variety of financial management positions at other companies, including roles as Corporate Controller, Manager of Internal Audit and Manager of Financial Reporting. Mr. Pfeffer began his career at Price Waterhouse. Mr. Pfeffer graduated from the University of California, Berkeley and is a Certified Public Accountant.- Matthew J. Pfeffer，2008年4月开始就是公司的副总裁和首席财务官。2006年3月到2008年4月，他是VaxGen公司的财务和行政管理部的首席财务官和高级副总裁，担任了责任越来越大的财政，税收，财政，人力资源，采购，设施功能职位。在加入公司前，他是细胞软件公司（Cell Genesys）的首席财务官。在他在细胞软件公司（Cell Genesys）的9年工作中，他是财务部主任，在1998年被任命为首席财务官前。在这之前，他在其他公司担任不同的财务管理职位任职，包括公司财务主管，内部审计经理和财务报告经理。他毕业于伯克利加利福尼亚大学（the University of California），是注册会计师。
- Matthew J. Pfeffer has served as our Chief Executive Officer and one of our directors since January 2016 and as our Chief Financial Officer since April 2008. Mr. Pfeffer also served as our Corporate Vice President from April 2008 until January 2016. Previously, Mr. Pfeffer served as Chief Financial Officer and Senior Vice President of Finance and Administration of VaxGen, Inc. from March 2006 until April 2008 with responsibility for finance, tax, treasury, human resources, IT, purchasing and facilities functions. Prior to VaxGen, Mr. Pfeffer served as CFO of Cell Genesys, Inc. During his nine year tenure at Cell Genesys, Mr. Pfeffer served as Director of Finance before being named CFO in 1998. Prior to that, Mr. Pfeffer served in a variety of financial management positions at other companies, including roles as Corporate Controller, Manager of Internal Audit and Manager of Financial Reporting. Mr. Pfeffer began his career at Price Waterhouse. Mr. Pfeffer graduated from the University of California, Berkeley and is a Certified Public Accountant.
- David B. Thomson
David B. Thomson，2002年1月开始就是公司的副总裁，总法律顾问和秘书。在加入我们之前他在多伦多一家大法律公司进行企业/商业和证券法实践。在他早期的事业中，他是美国洛克菲勒大学（the Rockefeller University）的博士后研究员。他获得了他获得皇后大学（Queens University）的学士学位，硕士学位，博士学位。他从多伦多大学（the University of Toronto）获得博士学位。
David B. Thomson has been our Corporate Vice President, General Counsel and Corporate Secretary since January 2002. Prior to joining us, he practiced corporate/commercial and securities law at a major Toronto law firm. Earlier in his career, Dr. Thomson was a post-doctoral fellow at the Rockefeller University. Dr. Thomson obtained his bachelor’s degree, master’s degree and Ph.D. from Queens University and obtained his J.D. from the University of Toronto.- David B. Thomson，2002年1月开始就是公司的副总裁，总法律顾问和秘书。在加入我们之前他在多伦多一家大法律公司进行企业/商业和证券法实践。在他早期的事业中，他是美国洛克菲勒大学（the Rockefeller University）的博士后研究员。他获得了他获得皇后大学（Queens University）的学士学位，硕士学位，博士学位。他从多伦多大学（the University of Toronto）获得博士学位。
- David B. Thomson has been our Corporate Vice President, General Counsel and Corporate Secretary since January 2002. Prior to joining us, he practiced corporate/commercial and securities law at a major Toronto law firm. Earlier in his career, Dr. Thomson was a post-doctoral fellow at the Rockefeller University. Dr. Thomson obtained his bachelor’s degree, master’s degree and Ph.D. from Queens University and obtained his J.D. from the University of Toronto.
- Stuart A. Tross
Stuart A. Tross， 他在2013年10月成为人力资源高级副总裁。他2006年4月加入本公司，担任人力资源副总裁。加盟Amgen公司之前，从1998年11月至2006年4月他在BMS担任了一系列职位，他的最后一个职位是Mead Johnson营养品部副总裁兼人力资源全球负责人。在加入BMS之前，他是Towers Perrin咨询的一位管理顾问。
Stuart A. Tross has been our Corporate Vice President, Chief People Officer since December 2016 with responsibilities for human resources, information technology and west coast facilities. From 2006 to 2016 he served in various roles of increasing responsibility at Amgen, Inc., most recently as Senior Vice President and Chief Human Resources Officer responsible for human resources and security on a global basis. From 1998 to 2006 he served in a series of leadership roles at Bristol-Myers Squibb Co, most recently as Vice President and Global Head of Human Resources for Mead Johnson Company. Stuart received a B.S. degree from Cornell University and M.S. and Ph.D. degrees in Industrial-Organizational Psychology from the Georgia Institute of Technology.- Stuart A. Tross， 他在2013年10月成为人力资源高级副总裁。他2006年4月加入本公司，担任人力资源副总裁。加盟Amgen公司之前，从1998年11月至2006年4月他在BMS担任了一系列职位，他的最后一个职位是Mead Johnson营养品部副总裁兼人力资源全球负责人。在加入BMS之前，他是Towers Perrin咨询的一位管理顾问。
- Stuart A. Tross has been our Corporate Vice President, Chief People Officer since December 2016 with responsibilities for human resources, information technology and west coast facilities. From 2006 to 2016 he served in various roles of increasing responsibility at Amgen, Inc., most recently as Senior Vice President and Chief Human Resources Officer responsible for human resources and security on a global basis. From 1998 to 2006 he served in a series of leadership roles at Bristol-Myers Squibb Co, most recently as Vice President and Global Head of Human Resources for Mead Johnson Company. Stuart received a B.S. degree from Cornell University and M.S. and Ph.D. degrees in Industrial-Organizational Psychology from the Georgia Institute of Technology.